ZLAB
Price:
$19.85
Market Cap:
$1.97B
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; and Qinlock to treat gastrointestinal stromal tumors. It also develops Odronextamab to treat follicular lymphoma, diffuse large B-cell lymphoma, and other B-celllymphomas; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in T...[Read more]
Industry
Biotechnology
IPO Date
2017-09-20
Stock Exchange
NASDAQ
Ticker
ZLAB
According to Zai Lab Limited’s latest financial reports and current stock price. The company's current PE Ratio is -6.40. This represents a change of -9.60% compared to the average of -7.08 of the last 4 quarters.
The mean historical PE Ratio of Zai Lab Limited over the last ten years is -23.24. The current -6.40 PE Ratio has changed 2.65% with respect to the historical average. Over the past ten years (40 quarters), ZLAB's PE Ratio was at its highest in in the December 2018 quarter at -4.82. The PE Ratio was at its lowest in in the December 2020 quarter at -38.69.
Average
-23.24
Median
-9.61
Minimum
-76.41
Maximum
-6.10
Discovering the peaks and valleys of Zai Lab Limited PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 126.75%
Maximum Annual PE Ratio = -6.10
Minimum Annual Increase = -76.06%
Minimum Annual PE Ratio = -76.41
Year | PE Ratio | Change |
---|---|---|
2023 | -7.89 | 29.34% |
2022 | -6.10 | -27.70% |
2021 | -8.44 | -76.06% |
2020 | -35.25 | 77.01% |
2019 | -19.92 | 126.75% |
2018 | -8.78 | -8.60% |
2017 | -9.61 | -73.82% |
2016 | -36.71 | -51.96% |
The current PE Ratio of Zai Lab Limited (ZLAB) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-7.48
5-year avg
-15.52
10-year avg
-23.24
Zai Lab Limited’s PE Ratio is less than C4 Therapeutics, Inc. (-3.44), less than Erasca, Inc. (-3.94), greater than Cullinan Oncology, Inc. (-6.96), greater than Legend Biotech Corporation (-30.94), greater than Seagen Inc. (-57.36), greater than Alnylam Pharmaceuticals, Inc. (-428.77), greater than Ascendis Pharma A/S (-12.57), less than Roivant Sciences Ltd. (0), less than Krystal Biotech, Inc. (1.91), less than Prometheus Biosciences, Inc. (49.72), greater than Akero Therapeutics, Inc. (-81.93), greater than Apellis Pharmaceuticals, Inc. (-8.95), greater than PTC Therapeutics, Inc. (-15.28), less than Blueprint Medicines Corporation (-5.05), greater than Intercept Pharmaceuticals, Inc. (-26.44), greater than Madrigal Pharmaceuticals, Inc. (-13.55), greater than null (-10.23),
Company | PE Ratio | Market cap |
---|---|---|
-3.44 | $374.42M | |
-3.94 | $807.96M | |
-6.96 | $1.04B | |
-30.94 | $9.90B | |
-57.36 | $43.15B | |
-428.77 | $31.68B | |
-12.57 | $6.83B | |
0 | $9.10B | |
1.91 | $5.29B | |
49.72 | $9.56B | |
-81.93 | $1.83B | |
-8.95 | $5.00B | |
-15.28 | $2.43B | |
-5.05 | $5.47B | |
-26.44 | $794.69M | |
-13.55 | $5.30B | |
-10.23 | $0 |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Zai Lab Limited using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Zai Lab Limited or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Zai Lab Limited's PE Ratio?
How is the PE Ratio calculated for Zai Lab Limited (ZLAB)?
What is the highest PE Ratio for Zai Lab Limited (ZLAB)?
What is the 3-year average PE Ratio for Zai Lab Limited (ZLAB)?
What is the 5-year average PE Ratio for Zai Lab Limited (ZLAB)?
How does the current PE Ratio for Zai Lab Limited (ZLAB) compare to its historical average?